207 related articles for article (PubMed ID: 21273047)
21. Detection of tyrosinase mRNA from the blood of melanoma patients.
Stevens GL; Scheer WD; Levine EA
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
23. Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma.
Altomonte M; Colizzi F; Esposito G; Maio M
N Engl J Med; 1992 Sep; 327(13):959. PubMed ID: 1355268
[No Abstract] [Full Text] [Related]
24. [Serum sialic acid bound to lipoproteins. Its contribution to the diagnosis and follow-up of melanoma].
Sánchez Conejo-Mir J; Sotillo Gago I; Camacho F; Iglesias Huertas R
Med Cutan Ibero Lat Am; 1990; 18(4):219-23. PubMed ID: 2077306
[TBL] [Abstract][Full Text] [Related]
25. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.
Bolander A; Agnarsdóttir M; Wagenius G; Strömberg S; Pontén F; Ekman S; Brattström D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
Melanoma Res; 2008 Dec; 18(6):412-9. PubMed ID: 19011512
[TBL] [Abstract][Full Text] [Related]
26. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
Pelletier F; Bermont L; Puzenat E; Blanc D; Cairey-Remonnay S; Mougin C; Laurent R; Humbert P; Aubin F
Br J Dermatol; 2005 Apr; 152(4):685-9. PubMed ID: 15840099
[TBL] [Abstract][Full Text] [Related]
27. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
28. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression.
Rusciani L; Proietti I; Rusciani A; Paradisi A; Sbordoni G; Alfano C; Panunzi S; De Gaetano A; Lippa S
J Am Acad Dermatol; 2006 Feb; 54(2):234-41. PubMed ID: 16443053
[TBL] [Abstract][Full Text] [Related]
29. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
[TBL] [Abstract][Full Text] [Related]
30. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of tyrosinase mRNA detected by nested RT-PCR in patients with malignant melanoma.
Glumac N; Snoj M; Hocevar M; Novakovic S
Neoplasma; 2006; 53(1):9-14. PubMed ID: 16416006
[TBL] [Abstract][Full Text] [Related]
32. Circulating melanoma cells and survival in metastatic melanoma.
Rao C; Bui T; Connelly M; Doyle G; Karydis I; Middleton MR; Clack G; Malone M; Coumans FA; Terstappen LW
Int J Oncol; 2011 Mar; 38(3):755-60. PubMed ID: 21206975
[TBL] [Abstract][Full Text] [Related]
33. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients.
Baldi A; Dragonetti E; Battista T; Groeger AM; Esposito V; Baldi G; Santini D
Anticancer Res; 2000; 20(5C):3923-8. PubMed ID: 11268478
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
35. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity.
Greco M; Mitri MD; Chiriacò F; Leo G; Brienza E; Maffia M
Cancer Lett; 2009 Oct; 283(2):222-9. PubMed ID: 19394758
[TBL] [Abstract][Full Text] [Related]
36. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Harpio R; Einarsson R
Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
[TBL] [Abstract][Full Text] [Related]
37. [Multiple primary malignant tumors in patients with malignant melanoma of the skin].
Landthaler M; Braun-Falco O; Bernreiter F; Hölzel D
Hautarzt; 1992 Jan; 43(1):11-5. PubMed ID: 1612903
[TBL] [Abstract][Full Text] [Related]
38. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers.
Ragazzi E; Vogliardi S; Allegri G; Costa CV; Lise M; Rossi CR; Seraglia R; Traldi P
Rapid Commun Mass Spectrom; 2003; 17(13):1511-5. PubMed ID: 12820221
[No Abstract] [Full Text] [Related]
39. Serum markers in skin melanoma--preliminary study.
Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
[TBL] [Abstract][Full Text] [Related]
40. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
